Clinical Trial Update: Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating nivolumab plus ipilimumab, with or without SBRT, in metastatic Merkel cell carcinoma; results posted May 19, 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma
• Skin Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Merkel Cell Carcinoma, Skin Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-19